HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kole, A. C. Articles by Molenaar, W. M. Search for Related Content PubMed PubMed Citation Articles by Kole, A. C. Articles by Molenaar, W. M.

FDG and L-[1-¹¹C]-Tyrosine Imaging of Soft-Tissue Tumors Before and After Therapy

PET Center, Departments of Surgical Oncology and Pathology, Groningen University Hospital, Groningen, The Netherlands

Correspondence: For correspondence or reprints contact: Willem Vaalburg, PhD, PET Center, Groningen University Hospital, PO Box 30.001, 9700 RB Groningen, The Netherlands.

ABSTRACT

This study was undertaken to investigate the relationship of PET using fluorodeoxyglucose (FDG) or L-[1-¹¹C]-tyrosine (TYR) with histopathologic findings in soft-tissue tumors, before and after therapy. Histopathologic parameters that were studied were tumor grade, mitotic rate, proliferation activity and amount of necrosis. Methods: PET with either FDG or TYR was performed in 55 patients with a lesion suspected to be a malignant soft-tissue tumor. In 28 patients, a second PET study was performed after therapy. Metabolic rate of glucose consumption (MRglc) and protein synthesis rate (PSR) were calculated. Histologic parameters were obtained from a biopsy specimen that was taken just after the first PET study and from the tumor remnant that was resected after therapy. Results: MRglc correlated with tumor grade (r = 0.71) and mitotic rate (r = 0.68) but not with proliferation or necrosis. After therapy, there was no longer a correlation with mitotic rate. PSR correlated with tumor grade (r = 0.53), mitotic rate (r = 0.73) and proliferation (r = 0.66). After therapy, correlation with mitosis and proliferation had improved, and a negative correlation was found between PSR and necrosis (r = –0.74). Conclusion: These results validate the use of both FDG and TYR to give an in vivo indication of histologie tumor parameters. However, FDG gives a better indication of tumor grade, whereas TYR is more accurate in predicting mitotic rate and proliferation, especially after therapy. FDG may therefore not be the most suited tracer for monitoring therapy. TYR might be more appropriate for that purpose.

Key Words: PET • histology • fluorodeoxyglucose • tyrosine • tumor

This article has been cited by other articles:

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977. [Abstract] [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				D. C. P. Cobben, P. H. Elsinga, A. J. H. Suurmeijer, W. Vaalburg, B. Maas, P. L. Jager, and H. J. Hoekstra Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3'-Fluoro-3'-Deoxy-L-Thymidine Clin. Cancer Res., March 1, 2004; 10(5): 1685 - 1690. [Abstract] [Full Text] [PDF]

				J. P.A. Ioannidis and J. Lau 18F-FDG PET for the Diagnosis and Grading of Soft-Tissue Sarcoma: A Meta-Analysis J. Nucl. Med., May 1, 2003; 44(5): 717 - 724. [Abstract] [Full Text] [PDF]

				R. Hustinx, C. Lemaire, G. Jerusalem, P. Moreau, D. Cataldo, B. Duysinx, J. Aerts, M.-F. Fassotte, J. Foidart, and A. Luxen Whole-Body Tumor Imaging Using PET and 2-18F-Fluoro-L-Tyrosine: Preliminary Evaluation and Comparison with 18F-FDG J. Nucl. Med., April 1, 2003; 44(4): 533 - 539. [Abstract] [Full Text] [PDF]

				J. R. de Boer, J. Pruim, B. F.A.M. van der Laan, T. H. Que, A. T.M. Willemsen, F. W.J. Albers, and W. Vaalburg L-1-11C-Tyrosine PET in Patients with Laryngeal Carcinomas: Comparison of Standardized Uptake Value and Protein Synthesis Rate J. Nucl. Med., March 1, 2003; 44(3): 341 - 346. [Abstract] [Full Text] [PDF]

				P. L. Jager, W. Vaalburg, J. Pruim, E. G.E. de Vries, K.-J. Langen, and D. A. Piers Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology J. Nucl. Med., March 1, 2001; 42(3): 432 - 445. [Abstract] [Full Text]

				P. L. Jager, B. E. C. Plaat, E. G. E. de Vries, W. M. Molenaar, W. Vaalburg, D. A. Piers, and H. J. Hoekstra Imaging of Soft-Tissue Tumors Using L-3-[Iodine-123]Iodo-{{alpha}}-methyl-tyrosine Single Photon Emission Computed Tomography: Comparison with Proliferative and Mitotic Activity, Cellularity, and Vascularity Clin. Cancer Res., June 1, 2000; 6(6): 2252 - 2259. [Abstract] [Full Text]